Caspase induction and BCL2 inhibition in human adipose tissue: a potential relationship with insulin signaling alteration

Diabetes Care. 2013 Mar;36(3):513-21. doi: 10.2337/dc12-0194. Epub 2012 Nov 27.

Abstract

Objective: Cell death determines the onset of obesity and associated insulin resistance. Here, we analyze the relationship among obesity, adipose tissue apoptosis, and insulin signaling.

Research design and methods: The expression levels of initiator (CASP8/9) and effector (CASP3/7) caspases as well as antiapoptotic B-cell lymphoma (BCL)2 and inflammatory markers were assessed in visceral (VAT) and subcutaneous (SAT) adipose tissue from patients with different degrees of obesity and without insulin resistance or diabetes. Adipose tissue explants from lean subjects were cultured with TNF-α or IL-6, and the expression of apoptotic and insulin signaling components was analyzed and compared with basal expression levels in morbidly obese subjects.

Results: SAT and VAT exhibited increased CASP3/7 and CASP8/9 expression levels and decreased BCL2 expression with BMI increase. These changes were accompanied by increased inflammatory cytokine mRNA levels and macrophage infiltration markers. In obese subjects, CASP3/7 activation and BCL2 downregulation correlated with the IRS-1/2-expression levels. Expression levels of caspases, BCL2, p21, p53, IRS-1/2, GLUT4, protein tyrosine phosphatase 1B, and leukocyte antigen-related phosphatase in TNF-α- or IL-6-treated explants from lean subjects were comparable with those found in adipose tissue samples from morbidly obese subjects. These insulin component expression levels were reverted with CASP3/7 inhibition in these TNF-α- or IL-6-treated explants.

Conclusions: Body fat mass increase is associated with CASP3/7 and BCL2 expression in adipose tissue. Moreover, this proapoptotic state correlated with insulin signaling, suggesting its potential contribution to the development of insulin resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / drug effects
  • Adipose Tissue / metabolism*
  • Caspase 3 / metabolism*
  • Caspase 7 / metabolism*
  • Caspase 8 / metabolism*
  • Caspase 9 / metabolism*
  • Glucose Transporter Type 4 / metabolism
  • Humans
  • Insulin / metabolism*
  • Interleukin-6 / metabolism
  • Intra-Abdominal Fat / drug effects
  • Intra-Abdominal Fat / metabolism
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1 / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / metabolism*
  • Signal Transduction / drug effects
  • Subcutaneous Fat / drug effects
  • Subcutaneous Fat / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Glucose Transporter Type 4
  • Insulin
  • Interleukin-6
  • Proto-Oncogene Proteins c-bcl-2
  • Tumor Necrosis Factor-alpha
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1
  • CASP3 protein, human
  • CASP7 protein, human
  • CASP8 protein, human
  • CASP9 protein, human
  • Caspase 3
  • Caspase 7
  • Caspase 8
  • Caspase 9